Affectis is developing AFC-5128, a potent CNS-penetrant P2X7 antagonist for the treatment of neuroinflammatory diseases.
P2X7 is an ATP-gated ion channel which is essential for the maturation and release of the pro-inflammatory cytokines, including interleukin-1beta (IL-1β). In certain circumstances, activation of P2X7 can lead to cell death. P2X7 antagonists capable of crossing the blood-brain barrier also have therapeutic potential in multiple sclerosis and neuropathic pain.
AFC-5128 is currently in preclinical development with IND filing planned in 2011 and initiation of phase I studies in neuropathic pain shortly thereafter.
Copyright © 2010 Affectis Pharmaceuticals AG. All Rights Reserved.